Angiogenesis

FLT3-IN-14: FLT3 inhibitor; FLT3-WT IC50=5.6nM, FLT3-ITD IC50=1.4nM; blocks Y591 phosphorylation; G1 arrest; pro-apoptotic.

Itacnosertib hydrochloride acts as an inhibitor targeting JAK2, ACVR1 (ALK2), and ALK5 [1].

UNC4203 inhibits MERTK (1.2 nM), AXL (140 nM), TYRO3 (42 nM), FLT3 (90 nM); potent, selective, oral.

BTK-IN-17: selective, oral BTK inhibitor, IC50=13.7 nM, reduces p-BTK Y223/p-PLCγ2 Y1217, anti-inflammatory.

EGFR-IN-85 (Compound 1), an EGFR inhibitor, exhibits potent activity with an IC50 of 0.19 μM against EGFRvⅢ phosphorylation and can suppress intratumoral EGFR

BTK inhibitor 13 (compound 8) is an effective and selective BTK inhibitor(IC50: 1.2 nM).

Atiprimod: an oral azaspirane inhibiting STAT3, blocking IL-6/VEGF pathways, and promoting apoptosis by downregulating Bcl-2 and Mcl-1.

"JAK-IN-17: Potent JAK inhibitor for studying ocular, skin, and respiratory diseases."

HIF-2α-IN-1 is a potent HIF-2α inhibitor with IC50 values less than 500 nM.

FGFR-IN-4 is a potent inhibitor of FGFR. FGFR-IN-4 has potential for cancer disease studies.

HPK1-IN-2 dihydrochloride, a potent and orally active inhibitor of hematopoietic progenitor kinase-1 (HPK1) with an IC 50 of less than 0.05 µM, demonstrates significant antitumor activity. It additionally exhibits inhibition of Lck kinase activity, with an IC 50 ranging from 0.05 to less than 0.5 µM, and Flt3 kinase activity, with an IC 50 of less than 0.05 µM [1].

JAK-IN-24: JAK inhibitor, IC50: 0.534 nM (4 μM ATP), 24 nM (1mM ATP), STAT5 phosphorylation IC50: 86.171 nM.

15-deoxy-Δ12,14-Prostaglandin D2 (15-deoxy-Δ12,14-PGD2) is a PGD2 metabolite functioning as an agonist for the PGD2 receptor 2 (DP2), with a binding affinity (Ki) of 50 nM for the mouse DP2 receptor expressed in HEK293 cell membranes. It activates eosinophils with an EC50 of 8 nM and enhances the recruitment of steroid receptor coactivator-1 (SRC-1) to peroxisome proliferator-activated receptor γ (PPARγ), initiating PPARγ-mediated transcription at 5 µM concentration. Furthermore, it exhibits cytotoxicity towards L1210 murine leukemia cells with an IC50 of 0.3 µg/ml and displays weaker inhibition of ADP-induced platelet aggregation than PGD2, with an IC50 of 320 ng/ml.

2'-Thioadenosine (PD157432) serves as a selective and irreversible inhibitor of ErbB-1 and ErbB-2 tyrosine kinases, demonstrating an IC50 value of 45 µM against

FC 11 is a reversible FAK PROTAC Degrader with DC50 of 40-370 pM and degrades pFAKtyr397 in TM3 cells within 3 hours at 100 nM.

HER2-IN-5 is an effective inhibitor of orally active HER-2.

Nazartinib is an EGFR inhibitor. Nazartinib S-enantiomer is the less active S-enantiomer of Nazartinib.

EGFR/CSC-IN-1 is a dual inhibitor targeting both the epidermal growth factor receptor (EGFR [IC50 10.52 nM]) and cancer stem cells (CSC), with potential

SNIPER(TACC3)-11 is a powerful FGFR3-TACC3 protein degrader, reducing its amount and hindering FGFR3-TACC3+ cancer cell growth.

HDAC-IN-63 (Compound 63) is a dual FLT3/HDAC inhibitor with IC50 values of 0.844 nM for FLT3 and 30.0 nM for HDAC1.